<DOC>
	<DOCNO>NCT02077569</DOCNO>
	<brief_summary>To compare effect four half day treatment range dose AZD5363 select marker AKT pathway anti-proliferation compare placebo oestrogen receptor positive breast cancer . To assess tolerability four half day treatment AZD5363 .</brief_summary>
	<brief_title>AKT Inhibitor Oestrogen Positive Breast Cancer</brief_title>
	<detailed_description>The principal research question address whether ( ) AZD5363 `` hit therapeutic target '' sufficiently extent require produce efficacy pre-clinical experiment . The primary endpoint marker select determine . Reductions marker AKT pathway increase marker anti-proliferation characterise degree biological activity arise inhibition AKT across range dos AZD5363 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Written inform consent 2. WHO performance status 01 . 3 . Able swallow &amp; retain oral medication . 4 . Patients fall either category ( ) ( b ) : 1 . Postmenopausal patient 2 . Premenopausal patient also meet least one criterion ( ) , ( ii ) ( iii ) : ) hysterectomy bilateral fallopian tube ligation least 6 week ago plus negative pregnancy test . ii ) true abstinence iii ) willing pregnancy test use 2 form contraception 5 . Female patient , age 18 year , histological confirmation ER positive invasive breast carcinoma . 6 . Stage 1/2/3 Stage 4 primary tumour breast amenable biopsy . New primary breast tumour ( ipsi contralateral ) despite prior endocrine treatment earlier primary breast tumour least 12 month interval cessation endocrine therapy Visit 1 eligible . 7 . Scheduled chemotherapy base tumour characteristic local treatment protocol . 8 . Tumours large enough provide sufficient tissue take corecut trucut biopsy provide tissue section marker assay . 1 . Prior treatment breast cancer except new primary breast tumour arise despote prior endocrine treatment earlier primary breas tumour least 12 month interval cessation endocrine therapy Visit 1 ( see inclusion criterion 6 ) . 2 . Known ER negative tumour . 3 . Female patient histological confirmation ER+ve invasive breast carcinoma schedule chemotherapy 4 . Exposure potent inhibitor inducer CYP3A4 CYP2D6 substrates CYP3A4 within 2 week first dose study treatment ( 3 week St Johns Wort ) . 5 . Clinically significant abnormality glucose metabolism 6 . Major surgery ( exclude placement vascular access ) within 4 week first dose study treatment . 7 . Spinal cord compression brain metastasis . 8 . Evidence severe uncontrolled systemic disease . 9 . Any following cardiac criterion : Mean rest correct QT interval ( QTc ) &gt; 450 msec obtain 3 consecutive ECGs ; Any clinically important abnormality rhythm , conduction morphology rest ECG Any factor increase risk QTc prolongation risk arrhythmic event . Any following procedure condition precede 6 month : coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , angina pectoris , congestive heart failure NYHA Grade 2 . Uncontrolled hypotension . 10 . Absolute neutrophil count &lt; 1.5 x 10,000,000,000/L 11 . Platelet count &lt; 100 x 10,000,000,000/L . 12 . Haemoglobin &lt; 90 g/L 13 . ALT &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastasis . 14 . Elevated ALP exclusionary due presence bone metastasis liver function otherwise consider adequate 15 . Total bilirubin &gt; 1.5 time ULN liver metastases &gt; 3 time ULN presence liver metastasis . 16 . Creatinine &gt; 1.5 time ULN concurrent creatinine clearance &lt; 50 ml/min ; confirmation creatinine clearance require creatinine &gt; 1.5 time ULN 17 . Proteinuria &gt; 3+ dipstick analysis . 18 . Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption AZD5363 . 19 . History hypersensitivity active inactive excipients AZD5363 drug similar chemical structure class AZD5363 . 20 . Current disease condition know interfere absorption , distribution , metabolism excretion drug . 21 . Past medical history interstitial lung disease , drug induce interstitial lung disease , radiation pneumonitis require steroid treatment , evidence clinically active interstitial lung disease . 22 . Evidence dementia , alter mental status psychiatric condition would prohibit understanding rendering informed consent 23 . Previous allogeneic bone marrow transplant . 24 . Known immunodeficiency syndrome . 25 . Pregnant lactating patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AKT inhibitor</keyword>
	<keyword>AZD5363</keyword>
	<keyword>Anti-tumour activity</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>ER positive</keyword>
	<keyword>Oestrogen positive</keyword>
	<keyword>post menopausal</keyword>
	<keyword>chemotherapy require</keyword>
	<keyword>prior cancer treatment</keyword>
</DOC>